Skip to main content
. 2021 Jul 27;15:11782234211034937. doi: 10.1177/11782234211034937

Figure 5.

Figure 5.

(A) Normal female Balb/cByJ mice treated with TE (400 µg/200 µL PBS) or vehicle for 4 days, spleens isolated and number of each cell type determined by flow cytometry. (B) Balb/cByJ or Balb/cSCID mice (5-6/group) treated with TE or PBS beginning on day 1 and continuing for 10 days. On day 4, mice injected with 1 × 105 line 66.1-luc tumor cells and on day + 19, lung metastases determined. PBS, Balb/cByJ versus TE, Balb/cByJ, P = .05. (C) On day 1, Balb/cByJ female mice (10/group) were treated with CD20 antibody or isotype control. On days 8 to 11, mice were treated with PBS or TE (400 µg/200 µL/day). On day 11, 1 × 105 of 66.1 cells injected IV. PBS or TE continued for an additional 6 days. On day 12, mice were again treated with either CD20 antibody or isotype control. Between days 14 and 21, mice were euthanized and lung metastases were enumerated. (D) On days + 1 to 10, Balb/cByJ female mice (10/group) were treated with PBS or TE (400 µg/200 µL/day). On days 3 and 7, mice were treated with asialo-GM1 antibody or normal rabbit serum. On day 4, 1 × 105 line 66.1 cells injected IV. On day 19, mice euthanized, and lung metastases were enumerated. PBS indicates phosphate-buffered saline; SCID, severe combined immune deficient; TE, taro extract.